XERIS PHARMACEUTICALS INC (XERS) [Rocket]

In millions, except per share items	Jun-30-21	Mar-31-21	Dec-31-20	Sep-30-20	Jun-30-20	Jun-05-20	Mar-31-20	Mar-05-20
	10-Q	8-K	10-K	10-Q	10-Q	8-K	10-Q	8-K
Net sales	33.3	26.5	20.2	13.1	3.7		1.7
Net sales growth	800.3%	1459.4%	1139.0%	27780.9%	7772.3%		3517.0%
Grant and other income	0.3	0.3	0.3	0.4	0.7		1.0
Cost of goods sold	9.6		9.3	5.9	3.1		1.8
Gross profit	22.3	17.5	11.1	7.6	1.3		0.9
Gross margin	66.9%	65.9%	55.1%	58.0%	35.1%		51.1%

Operating expenses:
Research and development	18.4	18.3	20.9	28.2	39.9		53.9
Selling, general and administrative	79.5	71.2	73.7	76.4	74.8		72.1
Total operating expenses	97.9	89.5	94.7	104.6	114.6		126.1
Loss from operations	-75.6	-72.0	-83.5	-97.0	-113.3		-125.2
Operating margin	-227.0%	-271.7%	-414.4%	-740.3%	-3063.3%		-7364.5%

Other income (expense):
Interest and other income	2.3		3.0	1.6	2.0		2.6
Interest expense	-10.5	-11.0	-10.7	-7.6	-8.8		-7.6
Change in fair value of warrants	-0.1		0.0	0.1	0.3		0.3
Total other income (expense)	-4.8	-5.1	-7.7	-5.9	-6.4		-4.7
Net loss before benefit from income taxes	-65.4		-91.3	-102.9	-119.8		-129.9
Benefit from income taxes			0.1		-0.1
Net loss	-83.8	-80.4	-91.1	-102.4	-119.2		-129.5

Other comprehensive income (loss), net of tax:
Unrealized gains (losses) on investments	-0.1
Foreign currency translation adjustments	0.0		0.0	0.0	0.0		0.0
Comprehensive loss	-27.5				-24.0

Net loss per common share - basic and diluted	($1.42)	($1.64)	($2.23)	($3.10)	($3.97)		($4.62)

Weighted average common shares outstanding - basic and diluted	54.1	47.0	39.9	35.8	31.0		28.2